MMEA
HAE icon

Main Management ETF Advisors’s Haemonetics HAE Stock Holding History

Main Management ETF Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
29,088
+720
+3% +$46.3K 0.07% 66
2026
Q1 		$1.6M Buy
+28,368
New +$1.85M 0.06% 73

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Main Management ETF Advisors's HAE Position: Q2 2026 in Review

Main Management ETF Advisors increased its Haemonetics (HAE) stake by 2.5% in Q2 2026, buying an estimated $46.3K and bringing the position to 29,088 shares worth $2.18M. The position accounts for 0.07% of the portfolio, ranked #66.

Main Management ETF Advisors first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Main Management ETF Advisors held 29,088 shares of Haemonetics worth $2.18M as of Q2 2026.
  • Main Management ETF Advisors bought 720 Haemonetics shares in Q2 2026, an estimated $46.3K.
  • Haemonetics made up 0.07% of Main Management ETF Advisors's portfolio in Q2 2026, its #66 holding.
  • Main Management ETF Advisors first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Main Management ETF Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.